Benefit is also seen with canaglifozin48 or dapaglifozin,84 but not with ertuglifozin.85 Three subsequent dedicated clinical trials were designed to test the effect of SGLT2i on CKD progression: CREDENCE,48 DAPA-CKD49 and EMPA-KIDNEY.50 The results from these studies have definitively confirmed the kidney-protective benefits of SGLT2i in patients with T2D and CKD and in a substudy of DAPA-CKD,86 those who continued with treatment after initiating dialysis had lower mortality levels compared to those who discontinued with it
GLP-1RAs and Renal Outcomes Accumulating clinical evidence demonstrates that GLP-1 RAs have beneficial effects on renal outcomes
The portal is built for scheduling, refills, and prescription tracking, while lifestyle advice comes only through brief provider guidance
Those are different questions and a purity figure is not evidence for any of them
Scientists are moving beyond isolated pathways and focusing on how multiple systems coordinate complex physiological responses
These results highlight the significance of controlling LC intake because an excess of this dietary component raises TMAO levels, which in turn raises cardiovascular risk